Labeled for this condition
Medicines for colorectal cancer
23 medicines have an FDA label indicated for colorectal cancer; 6 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for colorectal cancer?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Leucovorin | Vykoura | 16 labelers | $0.330 per tablet 5 mg tablet | No | No current entry | 9 |
| Fluorouracil | Favlyxa, Efudex, Tolak | 18 labelers | $0.616 per gram 5% cream | Yes | No current entry | 2 |
| Oxaliplatin | none listed | 16 labelers | n/a | Yes | A presentation being discontinued | 0 |
| Capecitabine | Xeloda | 18 labelers | $0.456 per tablet 500 mg tablet | Yes | No current entry | 4 |
| Irinotecan | Camptosar, Onivyde | 12 labelers | n/a | Yes | A presentation being discontinued | 9 |
| Bevacizumab | Zirabev, Avastin, Vegzelma | none listed | n/a | No | No current entry | 3 |
| Levoleucovorin | Khapzory | 8 labelers | n/a | No | No current entry | 0 |
| Aflibercept | Eylea, Zaltrap, Pavblu | none listed | n/a | No | No current entry | 2 |
| Nivolumab | Opdivo | none listed | n/a | No | No current entry | 1 |
| Sotorasib | Lumakras | none listed | n/a | No | No current entry | 0 |
| Berahyaluronidase alfa and pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 0 |
| Bevacizumab-maly | Alymsys | none listed | n/a | No | No current entry | 0 |
| Cetuximab | Erbitux | none listed | n/a | Yes | No current entry | 2 |
| Fruquintinib | Fruzaqla | none listed | n/a | No | No current entry | 0 |
| Ipilimumab | Yervoy | none listed | n/a | No | No current entry | 0 |
| Panitumumab | Vectibix | none listed | n/a | Yes | No current entry | 1 |
| Ramucirumab | Cyramza | none listed | n/a | No | No current entry | 1 |
| Tipiracil and trifluridine | Lonsurf | none listed | n/a | No | No current entry | 0 |
| Tucatinib | Tukysa | none listed | n/a | No | No current entry | 0 |
| Adagrasib | Krazati | none listed | n/a | No | No current entry | 0 |
| Encorafenib | Braftovi | none listed | n/a | No | No current entry | 0 |
| Pembrolizumab | Keytruda | none listed | n/a | No | No current entry | 1 |
| Regorafenib | Stivarga | none listed | n/a | Yes | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price